Magnetic Resonance Imaging (MRI) News and Research

RSS

Magnetic resonance imaging (MRI) uses a large magnet and radio waves to look at organs and structures inside your body. Health care professionals use MRI scans to diagnose a variety of conditions, from torn ligaments to tumors. MRIs are very useful for examining the brain and spinal cord. Also called: Magnetic resonance imaging, NMR, Nuclear magnetic resonance.

Alcohol binge-drinking in teen years could affect decision-making and related behaviors as adults

Adolescents represent the majority of people who binge drink. This may come as a surprise to some, but recent surveys indicate that episodes of heavy alcohol drinking within the previous two weeks are reported by 12 percent of 8th graders, 22 percent of 10th graders, 28 percent of 12th grade seniors and 44 percent of college students.

5 Apr 2011

First MR images to show complete borders in human cerebral cortex

Understanding functional properties of the brain’s structural units is one of the main aims of brain research. Until now only fragmentary borders of brain areas could be identified in vivo since the resolution in MR images was not high enough.

31 Mar 2011

Important updates on spondyloarthritis highlighted at 2010 SPARTAN meeting

Spondyloarthritis is a group of inflammatory conditions causing spine and joint pain and deformity, mostly in young men. Important updates on the epidemiology, diagnosis, and treatment of SpA are presented in the April issue of The American Journal of the Medical Sciences, official journal of the Southern Society for Clinical Investigation.

31 Mar 2011

Review questions diagnostic value of MRI scans to detect rupture of silicone breast implants

The U.S. Food and Drug Administration currently recommends regular follow-up magnetic resonance imaging (MRI) scans for women with silicone breast implants. But a new review shows significant flaws in the evidence supporting this recommendation, reports the March issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS).

28 Mar 2011

Study: Surgeon enthusiasm linked to high spinal procedure rates

Surgeons in some areas are more likely to recommend surgery for low back problems—and those differences in "surgeon enthusiasm" are a major factor driving regional variations in spinal surgery rates, suggests a study in the March 14 issue of Spine. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

25 Mar 2011

Mayo Clinic receives $1 million gift for Lewy body dementia study

To help continue its internationally recognized work in Lewy body dementia, the Harry T. Mangurian, Jr., Foundation has awarded Mayo Clinic a $1 million gift, pledged over four years. Lewy body dementia, which combines aspects of both Alzheimer's and Parkinson's diseases, is the second most common form of dementia in the United States.

23 Mar 2011

KYTHERA presents additional data from third ATX-101 Phase II clinical study in submental fat reduction

KYTHERA Biopharmaceuticals, Inc. today presented additional efficacy data from a third Phase II clinical study with ATX-101, a first-in-class adipolytic agent that is under investigation for the reduction of submental ('under the chin') fat. The expanded analysis focused on additional patient reported outcome measures, including instruments measuring submental fat impact, subject global assessments and subject self-ratings of chin attractiveness.

18 Mar 2011

Anti-cancer drug loaded microcarriers successfully guided to targeted area in the liver

Soon, drug delivery that precisely targets cancerous cells without exposing the healthy surrounding tissue to the medication's toxic effects will no longer be an oncologist's dream but a medical reality, thanks to the work of Professor Sylvain Martel, Director of the Nanorobotics Laboratory at Polytechnique Montr-al.

16 Mar 2011

Gadavist approved by FDA for use in central nervous system MRI scans

The U.S. Food and Drug Administration approved Gadavist (gadobutrol), a gadolinium-based contrast agent, for use in patients undergoing magnetic resonance imaging (MRI) of the central nervous system.

16 Mar 2011

Bayer receives FDA approval for Gadavist Injection

Bayer HealthCare Pharmaceuticals Inc. announced today that the U.S. Food and Drug Administration has approved Gadavist Injection, a macrocyclic gadolinium-based contrast agent, for intravenous use in diagnostic magnetic resonance imaging in adults and children to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system.

14 Mar 2011

Repligen reports positive results from RG1068 Phase 3 study to improve MRI of the pancreas

Repligen Corporation reported today positive top-line results from a Phase 3 study to evaluate the safety and efficacy of RG1068, synthetic human secretin, to improve magnetic resonance imaging (MRI) of the pancreas in patients with pancreatic disease using endoscopy (ERCP) as a diagnostic reference.

14 Mar 2011

International panel revises, simplifies 'McDonald Criteria' for diagnosis of multiple sclerosis

International Panel Revises "McDonald Criteria" for Diagnosing MS -- Use of new data should speed diagnosis -- Publication coincides with MS Awareness Week

10 Mar 2011

iCAD to showcase its cancer diagnostic imaging products at ECR annual meeting

iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of cancer, announces its featured products at the European Society of Radiology's annual meeting being held in Vienna, Austria from March 3 - 7, 2011.

3 Mar 2011

Genzyme reports 3-year follow-up data from eliglustat tartrate Phase 2 trial for Gaucher disease

Genzyme Corporation today announced three-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate. Sustained or further improvements were observed across all endpoints, including bone disease, at the three-year timepoint.

19 Feb 2011

Specific gene variation linked to late-onset Alzheimer's

A new study from the Centre for Addiction and Mental Health (CAMH) has found evidence suggesting that a variation of a specific gene may play a role in late-onset Alzheimer's, the disease which accounts for over 90% of Alzheimer's cases. This innovative study has combined genetics and brain imaging to determine who may be at risk for developing late-onset Alzheimer's disease long before symptoms appear.

9 Feb 2011

Researchers link brain's neural networks to specific cognitive functions

The human brain operates as a highly interconnected small-world network, not as a collection of discrete regions as previously believed, with important implications for why many of us experience cognitive declines in old age, a new study shows.

9 Feb 2011

Specific gene variation may play a role in late-onset Alzheimer's disease: New study

A new study from the Centre for Addiction and Mental Health has found evidence suggesting that a variation of a specific gene may play a role in late-onset Alzheimer's, the disease which accounts for over 90% of Alzheimer's cases. This innovative study has combined genetics and brain imaging to determine who may be at risk for developing late-onset Alzheimer's disease long before symptoms appear.

9 Feb 2011

Revo pacemaker receives FDA approval for use during certain MRI exams

The U.S. Food and Drug Administration today approved the first heart pacemaker designed to be used safely during certain magnetic resonance imaging (MRI) exams.

9 Feb 2011

FDA approves Medtronic's new Revo MRI pacemaker

Medtronic, today announced that the U.S. Food and Drug Administration approved its Revo MRI SureScan pacing system, the first and only pacemaker in the U.S. specifically designed for use in an Magnetic Resonance Imaging environment and approved as MR-Conditional. Shipments of Revo MRI will begin immediately.

8 Feb 2011

Schizophrenia patients who consume antipsychotics appear to lose small amount of brain tissue

Patients with schizophrenia who take antipsychotic medications appear to lose a small but measurable amount of brain tissue over time, according to a report in the February issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

8 Feb 2011

Magnetic Resonance Imaging (MRI) News and Research

Further Reading

Alcohol binge-drinking in teen years could affect decision-making and related behaviors as adults

First MR images to show complete borders in human cerebral cortex

Important updates on spondyloarthritis highlighted at 2010 SPARTAN meeting

Review questions diagnostic value of MRI scans to detect rupture of silicone breast implants

Study: Surgeon enthusiasm linked to high spinal procedure rates

Mayo Clinic receives $1 million gift for Lewy body dementia study

KYTHERA presents additional data from third ATX-101 Phase II clinical study in submental fat reduction

Anti-cancer drug loaded microcarriers successfully guided to targeted area in the liver

Gadavist approved by FDA for use in central nervous system MRI scans

Bayer receives FDA approval for Gadavist Injection

Repligen reports positive results from RG1068 Phase 3 study to improve MRI of the pancreas

International panel revises, simplifies 'McDonald Criteria' for diagnosis of multiple sclerosis

iCAD to showcase its cancer diagnostic imaging products at ECR annual meeting

Genzyme reports 3-year follow-up data from eliglustat tartrate Phase 2 trial for Gaucher disease

Specific gene variation linked to late-onset Alzheimer's

Researchers link brain's neural networks to specific cognitive functions

Specific gene variation may play a role in late-onset Alzheimer's disease: New study

Revo pacemaker receives FDA approval for use during certain MRI exams

FDA approves Medtronic's new Revo MRI pacemaker

Schizophrenia patients who consume antipsychotics appear to lose small amount of brain tissue

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News